modelC09CA03_1

Diagram of C09CA03_1

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Valsartan_1
ATC code:C09CA03_1
route:oral
compartments:1
dosage:160mg
volume of distribution:14.1L
clearance:2.17L/h
other parameters in model implementation

Valsartan is an angiotensin II receptor blocker (ARB) used for treating hypertension and heart failure and for protection after myocardial infarction.

Pharmacokinetics

Pharmacokinetic model in healthy adults after a single oral dose administration.

References

  1. Ngo, L, et al., & Lee, YB (2018). Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 118 154–164. DOI:10.1016/j.ejps.2018.03.031 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29604332

  2. Sioufi, A, et al., & Lloyd, P (1998). The effect of age on the pharmacokinetics of valsartan. Biopharmaceutics & drug disposition 19(4) 237–244. DOI:10.1002/(sici)1099-081x(199805)19:4<237::aid-bdd100>3.0.co;2-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9604123

  3. Iqbal, M, et al., & Sharma, PL (2010). Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clinical therapeutics 32(3) 588–596. DOI:10.1016/j.clinthera.2010.03.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20399995

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)